Cefaclor Capsules Rx
Generic Name and Formulations:
Cefaclor 250mg, 500mg; caps.
Various generic manufacturers
Indications for Cefaclor Capsules:
Susceptible infections including otitis media, lower respiratory or urinary tract, pharyngitis/tonsillitis, skin and skin structure.
250–500mg every 8 hrs.
<1month: not recommended. ≥1month: 20mg/kg per day in 3 equally divided doses. Otitis media, more serious or less susceptible infections: 40mg/kg per day in 3 equally divided doses (may give in 2 divided doses for pharyngitis or otitis media); max 1g/day.
Penicillin or other allergy. Discontinue if colitis occurs and treat. Severe renal dysfunction. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
May cause false (+) Coomb's test or glucose test with Clinitest or Benedict's or Fehling's soln. Potentiated by probenecid. Monitor warfarin. ER: antagonized by concomitant (within 1 hr) aluminum or magnesium-containing antacids.
Headache, GI upset, rash, blood dyscrasias, hepatic dysfunction, cough, CNS stimulation, serum-sickness-like reactions.
Formerly known under the brand names Ceclor CD (ext-rel tabs); Ceclor (caps, susp); Raniclor (caps).
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D